Louisiana Reclassifies Abortion Pills, Doctors Warn of Health Risks

Louisiana’s Reclassification of Abortion Pills Sparks Medical Concerns

As of this Tuesday, Louisiana has reclassified two common abortion pills, mifepristone and misoprostol, as controlled substances, a move that medical professionals fear will jeopardize women’s lives. The new law, unique to Louisiana, classifies the medications as schedule IV drugs—typically reserved for substances with potential for abuse or dependence—although pregnant women seeking the drugs for personal use are exempt from punishment.

Doctors are alarmed because these medications are not only used for abortions but also play a critical role in managing conditions such as postpartum hemorrhage, miscarriages, and even softening the cervix during labor. Dr. Nicole Freehill, an OB-GYN at a Louisiana hospital, expressed serious concerns about the impact this reclassification will have on emergency medical care. Previously, misoprostol was stored in accessible hemorrhage carts located in delivery rooms, allowing medical staff to retrieve it within seconds. Under the new rules, the drug is stored further away, and in a recent hospital drill, it took nurses two minutes to access the medication.

In critical situations, especially when a patient is actively hemorrhaging, those two minutes can result in significant blood loss, potentially costing lives. “Seconds count,” Freehill said, emphasizing the urgency in such medical emergencies.

The reclassification comes amid broader efforts by anti-abortion activists to limit access to abortion medications, especially after the overturning of Roe v. Wade. Although these medications are primarily associated with abortions, they serve vital purposes in a range of other medical scenarios. The decision has sparked significant backlash from the medical community. More than 200 doctors penned a letter to the legislator behind the law, warning that the additional regulation would cause delays in patient care and increase maternal mortality, particularly among Black women, who already face higher risks in childbirth in the U.S. compared to other wealthy nations.

Despite the rising number of abortions performed in clinics and self-managed with pills since the Roe reversal, doctors like Freehill argue there is no medical justification for reclassifying these drugs. The additional documentation and logistical hurdles will only complicate their ability to provide timely and effective care.

In Freehill’s words, “I don’t see how this is going to help my patients be safer.”

‍